The role of CR1 complement receptor in pathology;Rola receptora CR1 układu dopełniacza w patologii

Polski Merkuriusz Lekarski

Volumn 28, Issue 163, 2010, Pages 84-88

  Rochowiak, A ^a   Niemir, Z I ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CR1; HIV; Malaria; SLE; TP 10

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR;

ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; COMMUNICABLE DISEASE; COMPLEMENT ACTIVATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; METABOLISM; PHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; COMPLEMENT ACTIVATION; HIV INFECTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALARIA; RECEPTORS, COMPLEMENT 3B;

EID: 76749140884     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Arora M., Arora R., Tiwari S. C. et al.: Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus, 2000, 9, 127-131.
2. Arora M., Jain D., Dinda A. K. et al.: Reduced CR1 expression on erythrocytes of idiopathic focal-segmental glomerulosclerosis patients. Nephron, 1998, 79, 365-366.
3. Arora V., Mondai A.M., Graver R. et al.: Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-gamma and immune complex. Mol. Immunol., 2007, 44, 1722-1728.
4. Arora V., Verma J., Dutta R. et al.: Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus. Mol. Immunol., 2004, 41, 449-456.
5. Birmingham D. J., Gavit K. F., McCarty S.M. et al.: Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin. Exp. Immunol., 2006, 143, 274-280.
6. Birmingham D. J., Irshaid F., Gavit K. F. et al.: A polymorphism in the type one complement receptor (CR1) involves an additional cysteine within the C3b/C4b binding domain that inhibits ligand binding. Mol. Immunol., 2007, 44, 3510-3516.
7. Breman J. G.: The ears of hippopothamus: manifestation, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg., 2001, 64, 1-11.
8. Cockburn J. A., Mackinnon M. J., O'Donnell A. et al.: A human complement receptor 1 polymorphism that reduces Plasmodium falciparum resetting confers protection against severe malaria. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 272-277.
9. Cohen J. H., Geffriaud C., Caudwell V. et al.: Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. AIDS, 1989, 3, 397-9.
10. Cornillet P. Gredy P., Pennaforte J. L. et al.: Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin. Exp. Immunol., 1992, 89, 22-25.
11. Corvetta A., Pomponio G., Bencivenga R. et al.: Low number of complement C3b/C4b receptors (CR1) on erythrocytes from patients with essential mixed cryoglobulinemia, systemic lupus erythematosus, and rheumatoid arthritis: relationship with disease activity, antycardiolipin antibodies, complement activation and therapy. J. Rheumatol., 1991, 18, 1021-1025.
12. Couser W. G., Johnson R. J., Young B. A. et al.: The effects of soluble recombinant complement receptor 1 on complement mediated experimental glomerulonephritis. J. Am. Soc. Nephrol., 1995, 5, 1888-1894.
13. Da Silva R. P., Hall B. F., Joiner K. A. et al.: CR1, the C3 receptor, mediates binding of infective Leishmania major metacyciic promastigotes to human macrophages. J. Immunol., 1989, 143, 617-622.
14. Eror A. T., Stojadinovic A., Starnes B. W. et al.: Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin. Immunol., 1999, 90, 266-275.
15. Fyfe H., Holme E. R., Zoma A. et al.: C3b receptor (CR1) expression on the polymorphonuclear leukocytes from patient with systemic lupus erythematosus. Clin. Exp. Immunol., 1987, 67, 300-8.
16. Goodfellow R. M., Williams A. S., Levin J. L. et al.: Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin. Exp. Immunol., 2000, 119, 210-216.
17. Hamer I., Paccaud J. P., Belin D. et al.: Soluble form of complement C3bl C4b receptor (CR1) results from proteolytic cleavage in the C-terminal region of CR1 transmembrane domain. Biochem. J., 1998, 29, 183-190.
18. Hauptmann G., Tappeiner G., Schifferli J. A.: Inherited deficiency of fourth component of human complement. Immunodef. Rev., 1988, 1, 3-22.
19. Holme E., Fyfe A., Zoma A. et al.: Decreased C3b receptors (CR1) on erythrocytes from patients with systemic lupus erythematosus. Clin. Exp. Immunol., 1986, 63, 41-48.
20. Horakova E., Gasser O., Sadallah S. et al.: Complement mediates the binding of HIV to erythrocytes. J. Immunol., 2004, 173, 4236-4241.
21. Katyal M., Tiwari S. C., Kumar A. et al.: Association of complement receptor 1 (CR1, CD35, C3b/C4b receptor) density polymorphism with glomerulonephritis in Indian subjects. Mol. Immunol., 2004, 40, 1325-1332.
22. Khera R., Das N.: Complement receptor 1: Disease associations and therapeutic implications. Mol. Immunol., 2008, Nov 10-in pub.
23. Kubiak A., Olejniczak P., Czarnecki P. i wsp.: Analiza ekspresji ?-aktyny miȩśni gładkich oraz receptora dla składnika C3b dopełniacza w nerkach chorych na kłȩbuszkowe zapalenie nerek. Now. Lek., 2003, 72, 3-8.
24. Kumar A., Malaviya A. N., Srivastava L. M. et al.: Lowered expression of C3b receptor (CR1) on erythrocytes of rheumatoid arthritis patients. Immunobiology, 1994, 191, 9-20.
25. Lam T. T., Hausen B., Hook L. et al.: The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Xenotransplantation, 2005, 12, 20-29.
26. Lazar H. L., Bao Y. S., Gaudiani J. et al.: Total complement inhibition - an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation, 1999, 100, 1438-1442.
27. Lazar H. L., Bokesch P. M. Van Venta F. et al.: Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patient at high risk requiring cardiopulmonary bypass. Circulation, 2004, 110, II274-II279.
28. Lazar H. L., Hamasaki T., Bao Y. et al.: Soluble complement receptor type 1 limits damage during revascularization of ischemic myocardium. Ann. Thorac. Surg., 1998, 65, 973-7.
29. Lehmann T. G., Koeppel T. A., Kirschfink M. et al.: Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation, 1998, 66, 717-722.
30. Li J. S., Sanders S. P., Perry A. E. et al.: Pharmacokinetiks and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am. Heart J., 2004, 147, 173-180.
31. Makrides S. C., Nygren P. A., Andrews B. et al.: Extended in vivo half-life of human soluble complement receptor type 1 fused to e serum albumin-binding receptor. J. Pharmacol. Exp. Ther., 1996, 277, 534-542.
32. Manzi L., Montano R., Abad M. J. et al.: Expression of human soluble complement receptor 1 by a pig endothelial cell line inhibits lysis by human serum. Xenotransplantation, 2006, 13, 75-79.
33. Marquait H. V., Svendsen A., Rasmussen J. M. et al.: Complement receptor expression and activation of the complement cascade on B-lymphocytes from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol., 1995; 101, 60-65.
34. Metcalfe R. A., Mcintosh R. S., Morgan B. P. et al.: The effect of soluble complement receptor 1 (sCR1) and human thyroid antibodies on the course of experimental autoimmune thyroiditis in rats. Autoimmunity, 1996, 23, 1-8.
35. Mikata S., Miyagawa S., Yoshitatsu M. et al.: Prevention of hyperacute rejection by phosphatidylinositol-anchored mini-complement receptor type 1. Transpl. Immunol., 1998, 6, 107-110.
36. Mollnes T. E., Kirschfink M.: Strategies of therapeutic complement inhibition. Mol. Immunol., 2006, 43, 102-121.
37. Mollnes T. E., Song W. C., Lambris J. D. et al.: Complement in inflammatory tissue damage and disease. Trends. Immunol., 2002, 23, 61-64.
38. Morgan B. P., Marchbank K. J., Longhi M. P. et al.: Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett., 2005, 97, 171-179.
39. Mouhoub A., Delibrias C. C., Fischer E. et al.: Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin. Exp. Immunol., 1996, 106, 297-303.
40. Moulds J. M., Kassambara L., Middleton J. J. et al.: Identification of complement receptor one (CR1) polymorphism in West Africa. Genes. Immun., 2000, 1, 325-329.
41. Moulds J. M., Reveille J. D., Arnett F. C.: Structural polymorphism of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) patient and normal controls of three ethnic groups. Clin. Exp. Immunol., 1996, 105, 302-305.
42. Nagayasu E., Ito M., Akaki M. et al.: CR1 density polymorphism on erythrocytes of Falciparum malaria patients in Thailand. Am. J. Trop. Med. Hyg., 2001, 64, 1-5.
43. Nangaku M.: Complement regulatory proteins in glomerular diseases. Kidney Int., 1998, 54, 1419-1428.
44. Oudin S., Libyh M. T., Goossens D. et al.: A soluble recombinant multi-meric anty-Rh(D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes. J. Immunol., 2000, 164, 1505-1513.
45. Panchamoorthy G., Tiwari S. C., Srivastava L. M.: Inherited structural and quantitative polymorphism of C3b receptor (CR1) in normals and patients with glomerular diseases. Asian. Pac. J. Allergy. Immunol., 1993, 11, 123-129.
46. Pascual M., Danielsson C., Steiger G. et al.: Proteolytic cleavage of CR1 on human erythrocytes in vivo: evidence for enhanced cleavage in AIDS. Eur. J. Immunol., 1994, 24, 702-8.
47. Pascual M., Steiger G., Sadallah S. et al.: Identification of membrane-bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes. J. Exp. Med., 1994, 179, 889-899.
48. Payne N. R., Horwitz M. A.: Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors. J. Exp. Med., 1987, 166, 1377-39.
49. Pratt J. R., Hibbs M. J., Laver A. J. et al.: Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am. J. Pathol., 1996, 149, 2055-2066.
50. Pruitt S. K., Baldwin W. M. III, Marsh H. C. Jr et al.: The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation, 1991, 52, 868-73.
51. Pruitt S. K., Bollinger R. R.: The effect of soluble complement receptor type one on hyperacute allograft rejection. J. Surg. Res., 1991, 50, 350-355.
52. Pruitt S. K., Kirk A. D., Bollinger R. R. et al.: The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation, 1994, 57, 363-370.
53. Rabinovici R., Yeh C. G., Hillegass L. M. et al.: Role of complement in endotoxin/platelet-activating factor-induced lung injury. J. Immunol., 1992, 149, 1744-1750.
54. Raju K. R., Sivasankar B., Anand V. et al.: Use of complement receptor 1 (CD35) assay in the diagnosis and prognosis of immnune complex mediated glomerulopathies. Asian. Pac. J. Allergy Immunol., 2001, 19, 23-27.
55. Rioux P.: TP-10 (AVANT immunotherapeutics). Curr. Opin. Investig. Drugs, 2001, 2, 364-371.
56. Ross G. d., Lambris J. D., Cain J. A. et al.: Generation of three diffrent fragments of bound C3 with purified factor I or serum. II. Requirements for factor H vs. CR1 cofactor activity. J. Immunol., 1982, 129, 2051-2060.
57. Ross G. D., Yount W. J., Walport M. J. et al.: Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J. Immunol., 1985, 135, 2005-2014.
58. Rowe J. A., Moulds J. M., Newbold C. I. et al.: P. falciparum resetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature, 1997, 388, 292-295.
59. Rowe J. A., Raza A., Diallo D. A. et al.: Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. Genes. Immun., 2002, 3, 497-500.
60. Ruuska P. E., Ikaheimo I., Silvennoinen-Kassinen S. et al.: Normal C3b receptor (CR1) genomic polymorpgism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon? Clin. Exp. Immunol., 1992, 89, 18-21.
61. Scesney S. M., Makrides S. C., Gosselin M. L. et al.: A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur. J. Immunol., 1996, 26, 1729-1735.
62. Schlesinger L. S., Bellinger-Kawahara C. G., Payne N. R. et al.: Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol., 1990, 144, 2771-2780.
63. Shandelya S. M. L., Kuppusamu P., Herskowitz A. et al.: Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation, 1993, 88, 2812-2826.
64. Tausk F. A., McCutchan J. A., Spechko P. et al.: Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual menin varying risk groups for acquired immune deficiency syndrome. J. Clin. Invest., 1986, 78, 977-82.
65. Thieblemont N., Haeffner-Cavaillon N., Haeffner A. et al.: Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J. Immunol., 1995, 155, 4861-7.
66. Thomas B. N., Donvito B., Cockburn I. et al.: A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa. Genes Immun., 2005, 6, 31-36.
67. Van Dyne S., Holers M. V., Lublin D. M. et al.: The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin. Exp. Immunol., 1987, 68, 570-579.
68. Walport M. J., Ross G. D., Mackworth-Young C. et al.: Family studies of erythrocyte complement type 1 levels: reduced levels in patient with SLE are acquired, not inherited. Clin. Exp. Immunol., 1985, 59, 547-54.
69. Weis J. H., Morton C. C., Bruns G. A. P. et al.: A complement receptor locus: genes encoding C3b/C4b receptor and Cad/Epstein-Barr virus receptor map to 1q32. J. Immunol., 1987, 138, 312-5.
70. Weisman H. F., Bartow T., Leppo M. K. et al.: Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans. Assoc. Am. Physicians., 1990, 103, 64-72.
71. Weisman H. F., Bartow T., Leppo M. K. et al.: Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science, 1990, 249, 146-151.
72. Weiss L., Fischer E., Haeffner-Cavaillon N. et al.: The human C3b receptor (CR1). Adv. Nephrol. Necker. Hosp., 1989, 18, 249-269.
73. Wilson J. G., Murphy E. E., Wong W. W. et al.: Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J. Exp. Med., 1986, 164, 50-59.
74. Wilson J. G., Ratnoff W. D., Schur P. H. et al.: Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on lymphocytes B and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum., 1986, 29, 739-147.
75. Wilson J. G., Wong W. W., Murphy III E. E. et al.: Deficiency of the C3b/C4b receptor (CR1) of erythrocytes in systemic lupus erythematosus: analysis of the stability of the defect and of a restriction fragment length polymorphism of the CR1 gene. J. Immunol., 1987, 138, 2708-2710.
76. Wong W. W., Cahill J. M., Rosen M. D. et al.: Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J. Exp. Med., 1989, 169, 847-63.
77. Xiang L., Rundles J. R., Hamilton D. R. et al.: Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups. J. Immunol., 1999, 163, 4939-4945.
78. Zimmerman J. L., Dellinger R. P., Straube R. C. et al.: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med., 2000, 28, 3149-3154.